Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 2Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 3Other hematologic neoplasm 2Tumor-Agnostic 1Plasma cell 1Lymphoid 1Endocrine 1

Conditions

Vomiting 1Neoplasms, Plasma Cell 1Nausea 1

Interventions

Dexamethasone 393Bortezomib 246Lenalidomide 222Cyclophosphamide 184Melphalan 168Calcium Dobesilate 119Peripheral Blood Stem Cell Transplantation 94fludarabine phosphate 89Thalidomide 82Filgrastim 74carfilzomib 70pomalidomide 68Granulocyte Colony-Stimulating Factor 63Busulfan 63Mycophenolic Acid 61daratumumab 58Whole-Body Irradiation 57ixazomib 54fludarabine 52Tacrolimus 52Prednisone 51Cyclosporine 50Antilymphocyte Serum 35dexamethasone acetate 32plerixafor 30Etoposide 30Methotrexate 29Radiotherapy 28dexamethasone 21-phosphate 27Doxorubicin 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Olanzapine × Plasma cell × Clear all
NCT02939287 2024-10-22

Aprepitant- and Olanzapine- Containing Anti-emetic Regimens With High Dose Melphalan

Rush University Medical Center

Phase 3 Completed
52 enrolled 11 charts
Plasma cell

Nausea, Vomiting, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡